title: Consequences of a benzodiazepine discontinuation programme in family practice on psychotropic medication prescription to the participants.
abstract: BACKGROUND
  Whether long-term benzodiazepine users who participate in a family practice-based benzodiazepine discontinuation programme substitute benzodiazepines by other psychotropics is not clear.
  
  
  OBJECTIVE
  To evaluate the impact of a benzodiazepine discontinuation programme on non-benzodiazepine psychotropic prescription in family practice.
  
  
  METHODS
  In family practices in the Netherlands, 2425 long-term benzodiazepine users participated in a two-step benzodiazepine discontinuation programme. The programme started with a discontinuation letter (Step 1). Subjects unable to stop (N = 1707) were offered participation in Step 2, a three-group randomized trial with a taper procedure with group psychotherapy, a taper without psychotherapy and usual care. Only 156 subjects agreed to participate. The comparison group consisted of 1821 long-term users from family practices not participating in the programme. The main outcome was the change in prescription of non-benzodiazepine psychotropic medication from baseline (3 months before the start of the programme) till 21 months after the start of the programme. Four logistic regression models were performed concerning antidepressant prescription in the follow-up.
  
  
  RESULTS
  Only antidepressants were prescribed in relevant numbers. The prescription of antidepressants was not related to the programme. (P-value of experimental versus control group varied between 0.18 and 0.85 in the four models). The most important predictor of antidepressant prescription in follow-up was baseline antidepressant prescription [odds ratio (OR): 67.2; 95% confidence interval (95% CI): 49.8-90.7]. Subjects, of whom the prescription of benzodiazepines had been discontinued completely, had been prescribed less antidepressants (OR: 0.8; 95% CI: 0.6-1.0).
  
  
  CONCLUSIONS
  An effective benzodiazepine reduction programme was not accompanied by a substitute use of other psychotropics.
authors.affiliation: Department of General Practice and Family Medicine, University Medical Centre St Radboud, Nijmegen, The Netherlands. w.gorgels@hag.umcn.nl
authors.forename: W J M J
authors.initials: WJ
authors.lastname: Gorgels
authors.forename: R C
authors.initials: RC
authors.lastname: Oude Voshaar
authors.forename: A J J
authors.initials: AJ
authors.lastname: Mol
authors.forename: E H
authors.initials: EH
authors.lastname: van de Lisdonk
authors.forename: J
authors.initials: J
authors.lastname: Mulder
authors.forename: H
authors.initials: H
authors.lastname: van den Hoogen
authors.forename: A J L M
authors.initials: AJ
authors.lastname: van Balkom
authors.forename: M H M
authors.initials: MH
authors.lastname: Breteler
authors.forename: F G
authors.initials: FG
authors.lastname: Zitman
mesh_terms: D000368:Aged; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D017723:Drug Utilization Review; D005194:Family Practice; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D010349:Patient Compliance / Q000706:statistics & numerical data*; D011446:Prospective Studies; D011619:Psychotropic Drugs / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control* / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D011619:Psychotropic Drugs; D001569:Benzodiazepines